About the Study

Acute Myeloid Leukemia (AML) and Acute Leukemia of Ambiguous Lineage (ALAL): A study using revumenib in combination with other chemotherapy drugs

This study is for patients who: • Are greater than 1 year old and less than 30 years old • Have refractory/persistent (has not responded to treatment) AML/ALAL or relapsed (has come back) AML/ALAL This study is being done to find out if revumenib in combination with other chemotherapy drugs is safe and effective in treating relapsed or refractory AML or ALAL in children, adolescents, and young adults.

Interested in learning more?

Full Study Name: RAVAML